Welcome to NorthStar’s newsroom
Filter Your Results
BELOIT — Company growth at NorthStar Medical Radioisotopes remains uninterrupted by COVID-19, according to CEO Steve Merrick. Work continues at the headquarters on a new electron accelerator production building to expand capacity of the company’s non-uranium domestic supply of molybdenum-99 (Mo-99). Read more…
NorthStar Medical Technologies is moving further into the cardiac imaging space after signing a new licensing agreement with St. Louis-based Capella Imaging, the companies announced Tuesday. As part of the deal, the Beloit, Wisconsin-based radioisotope company has acquired exclusive rights from Capella to develop and investigate a new fibrin-targeted diagnostic imaging agent used in single-photon
When industry, academia, the U.S. government and scientific and professional societies share a common vision to address a medical supply need, the results can benefit patient healthcare. Such was the case in securing a reliable domestic supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for the United States. Read more…
Medical radioisotopes are crucial components of modern health care, but the supply chain that ensures access to them is fragile. For example, SNMMI issued a molybdenum-99 (Mo-99) shortage alert for the first half of November, due to a continuing outage at a reactor in South Africa and an unanticipated shutdown of a reactor in the
– ORNL, others provide R&D help to make molybdenum-99 and technetium-99m without highly enriched uranium – “Made in the USA.” That can now be said of the radioactive isotope molybdenum-99 (Mo-99), last made in the United States in the late 1980s. Read more…
The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) took steps in February to ensure a stable and secure supply of a critical radioactive imaging tracer used to detect potentially life-threatening diseases. Read more…
– System will be the US’s first domestic source of molybdenum-99 for 30 years – The US Food and Drug Administration (FDA) has approved a new system for generating the diagnostic radioisotope technetium-99m that it hopes will address shortages. Read more…
A Wisconsin company has moved one step closer to becoming the first domestic producer in decades of a crucial medical radioisotope after receiving a key approval from the FDA on Thursday. Read more…
WASHINGTON (Reuters) – The U.S. federal government on Thursday approved a device made by a private company in Wisconsin that will allow the first domestic production of a medical imaging isotope in 25 years, a move the government said would enhance national security by reducing the need to transport weapons-grade uranium. Read more…
WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more…
Today, I’m proud to acknowledge the role the FDA played in the groundbreaking effort to develop a new imaging technology – the RadioGenix System. Read more…
WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more…
FDA Media Transcripts: https://www.fda.gov/NewsEvents/Newsroom/MediaTranscripts/default.htm Listen to FDA Media Briefing: [player id=1469]
FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging. Read more…
NorthStar Medical Radioisotopes’ Radiogenix™ Isotope Separation System’s product packaging is convenient, intuitive, creative and unconventional. Read more…
According to NNSA, NorthStar Medical Radioisotopes is to receive $5.2 million to further develop its technology to produce Mo-99 via neutron capture, bringing the total NNSA support for the project to $16.1 million to date. Read more…
NorthStar also signed a similar agreement with Triad Isotopes, Inc. in June. Read more…
MADISON, Wis., Aug 14, 2014 (BUSINESS WIRE) — NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company GE, -0.42% marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). Read more…
Twelve years ago George Messina met with a scientist about a new patent that would likely change how medical diagnostic testing would be done in the United States. Read more…
BELOIT (WIFR) — One medical company is bringing more jobs to the Beloit area, but that may not be the biggest factor of the move. Read more…
BELOIT, Wis. – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Read more…
Everybody loves the entrepreneur, the little guy or gal with the big idea who launches and expands a business. Politicians of every stripe correctly tout start-up companies as key to creating more jobs. Read more…
What does it say about a state’s innovation-based economy when it boasts not one but two of the four U.S. companies racing to produce a medical isotope so essential that it’s used in 50,000 clinical tests per day? Read more…
WASHINGTON, D.C. – The National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative announced today the signing of a cooperative agreement with NorthStar Medical Radioisotopes, LLC, to further the development of accelerator-based technology to produce molybdenum-99 (Mo-99) in the United States. Read more…
NorthStar Medical Radioisotopes LLC said Tuesday it has signed a $4.6 million agreement with the National Nuclear Security Administration that will help the Madison company develop architectural and site plans for a Beloit plant to produce medical isotopes. Read more…
As problems go, NorthStar Medical Radioisotopes LLC was founded on a big one. Production issues at several nuclear power plants outside the U.S. during the last few years and worries about nuclear proliferation prompted the federal government in 2009 to look for ways to make a critical medical isotope more safely and closer to home. Read more…
NorthStar Medical Radioisotopes has entered a tentative deal with GE Hitachi Nuclear Energy and Exelon for the production of the medical isotope molybdenum-99. Read more…
NorthStar Medical Radioisotopes LLC, a Madison nuclear medicine company, has signed a tentative agreement for its Beloit facility to process radioactive material into a key isotope used for medical procedures. Read more…
MADISON, Wis.–(BUSINESS WIRE)–Six Wisconsin bioscience companies have been selected as the winners of BioForward’s 2011 Emerging Company Showcase. Read more…
NorthStar Medical Radioisotopes, LLC plans to locate a new 82,000 square foot production facility in Beloit. Read more…
NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 people by 2016. Read more…
NorthStar Medical Radioisotopes, Madison, will build an 82,000-square-foot manufacturing plant in Beloit. Read more…
NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 workers by 2016. Read more…
A highly-specialized company serving the needs of the nuclear medicine market plans to locate its $194 million, 82,000-square foot production facility in Beloit. Read more…
Filter Your Results
BELOIT, Wis., October 5, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of Chief Financial Officer Paul Estrem, to Executive Vice President. Mr. Estrem has also been appointed to the NorthStar Board of Managers, effective October 12, 2020, and
BELOIT, Wis., September 17, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Company’s Beloit, Wis. headquarters on September 11, 2020. His travel to Wisconsin underscored the Department of Energy’s commitment to
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop
July 23, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer,
BELOIT, Wis. – July 8, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) webinar, “Industry Outlook on Current and Future Mo-99 Supply.” James Harvey, PhD, Chief Scientific Officer of
Chicago, IL and Beloit, WI, June 16, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier
– Award Recognizes Outstanding Contributions to Isotopes and Their Uses to Benefit Mankind – BELOIT, Wis., April 14, 2020 — NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it has received the President’s Award from the World Council on Isotopes (WCI). The
March 19, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer,
Highlights include: Company marks reliable U.S. Mo-99 production and supply for customers despite ongoing domestic industry supply shortages FDA approval of RadioGenix System version 1.2 enhancements Initiatives for increased domestic Mo-99 production capacity on track: U.S. Food and Drug Administration (FDA)-approved Mo-99 filling lines; isotope processing and accelerator production facilities construction on schedule Strategic acquisition
− Acquisition of technetium-99m (Tc-99m) SPECT agent expands company portfolio as strategic complement to commercially available RadioGenix® System − − Builds on NorthStar’s leadership expertise in development and commercialization of novel radiopharmaceuticals – − Exploratory Phase 1 study planned to investigate FibroScint (Tc-99m F4A) use in identifying thrombus in heart failure patients with assisted devices;
− State-of-the art equipment to increase production efficiency and output for U.S.-based Mo-99 supply – Beloit, Wis., February 18, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the addition of two
BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply
BELOIT, Wis. – January 21, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ‒ 20, 2020, in Dana Point, Ca. The Emerging Medtech Summit 2020
BELOIT, Wis. – December 16, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2020, being held January 13 ‒ 15, 2020, in San Francisco, Ca. Biotech Showcase is an investor conference focused
− RadioGenix® Systems have enabled reliable technetium 99m (Tc-99m) supply for patients’ diagnostic imaging procedures since product launch, despite ongoing industry supply shortages – Beloit, Wis., November 27, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, announced a landmark for its RadioGenix System
– Marking NorthStar expansion progress to increase U.S. production of non-highly enriched uranium produced molybdenum-99 (Mo-99), used in producing important medical isotope technetium-99m (Tc-99m) ‒ ‒ Recognizing RadioGenix® System contributions in addressing ongoing Mo-99 supply shortages by providing customers with nearly a year of continuous medical radioisotope supply since launch ‒ Beloit, Wis., October 14,
‒ Voting Begins September 9, 2019 at www.madeinwis.com ‒ Beloit, Wis., September 9, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the 4th Annual Coolest Thing Made in Wisconsin contest. The event highlights Wisconsin’s vibrant manufacturing industry, its
‒ Panel to discuss domestic Tc-99m radioisotope production, role of nuclear diagnostics and treatments in advancing personalized medicine – BELOIT, Wis. – August 28, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Atoms for
Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program. As part of the collaboration, NorthStar has provided a RadioGenix® System to the College of Pharmacy for use in training
– Supports enhancements for commercially available RadioGenix® System and technology to increase NorthStar’s current production capacity of non-uranium based Mo-99 – BELOIT, Wis. – July 23, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it has been awarded $15 million
─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis. – July 16, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator
BELOIT, Wis. – June 12, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca. Presentation topics encompass ongoing domestic
BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”). NorthStar received $75 million
– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis. – March 29, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment
– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m)
BELOIT, Wis. – December 18, 2018 –NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer. Mr. Estrem holds financial responsibility for the operations of company, reporting to President and Chief
– Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting – Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S. Department of Energy’s National Nuclear Security
– Former Chairman and CEO George Messina named Chairman Emeritus; appointed President and Chief Executive Officer of NorthStar Nuclear Therapies LLC – – Diane Hendricks appointed as Chairperson of the Board – BELOIT, Wis. – Sept. 14, 2018 – The Board of Managers of NorthStar Medical Technologies, LLC (“NorthStar” or the “Company”), a global innovator
– Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 – BELOIT, Wis. – July 24, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced
BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23
BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT)
– Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years – BELOIT, Wis. – April 30, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in
– Enables domestic Mo-99 supply produced without uranium for U.S. healthcare – – First U.S. source of medical radioisotope Mo-99 in more than 25 years – BELOIT, Wis. – February 8, 2018 – NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food
Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea Biopharmaceuticals. She joins NorthStar as it advances toward U.S. Food and Drug Administration (FDA) approval of its RadioGenix™ intelligent isotope separation system and its non-fission, non-uranium-based brand of
BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The award supports the process’
ST. LOUIS (Sept. 13, 2016) – At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use
BELOIT, Wis. (Sept. 12, 2016) – NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering. Brodack oversees day-to-day regulatory and quality operations at NorthStar. Milunas spearheads research and development. product design and engineering, with a strong focus on product development and
BELOIT, Wis. (June 10, 2016) – NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A
BELOIT, Wis. – NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include
BELOIT, Wis. – Stephen Merrick has joined NorthStar Medical Radioisotopes LLC as Senior Vice President and Chief Operating Officer, a newly created position with the company. Merrick brings 24 years of experience in the biotechnology/pharmaceutical/life sciences sector, having held multiple executive positions with leading global companies. He will oversee day-to-day operations at NorthStar – including engineering, production and customer
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). NNSA provided $8.86 million to support NorthStar’s neutron capture production process and $2.89 million for the company’s accelerator production process.
MADISON, Wis. – NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. This collaboration is
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope.
MADISON, Wis. – James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting & Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Harvey
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Under the terms of the cooperative agreement
Madison, Wis. – August 14, 2014 – NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). 99Mo is the parent isotope of 99mtechnetium (99mTc), the most widely
BELOIT, Wis. – July 22, 2014 – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Video Courtesy WKOW News NorthStar Medical Radioisotopes Breaks Ground
WASHINGTON, D.C. – July 15, 2014 – NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99), according to NorthStar’s chief science officer, James T. Harvey, Ph. D. Harvey provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here,
MADISON, Wis. – June 30, 2014 – NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission
ST. LOUIS, MO – June 7, 2014 – Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc. The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through
MADISON, WI – November 21, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to
MADISON, WI – September 17, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds
MADISON, WI – March 20, 2013 – NorthStar Medical Technologies, LLC, (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA). The FDA has accepted the application for review. The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical
MADISON, WI. – November 15, 2012 – NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative. The cooperative agreement marks successful completion of an Environmental Assessment of NorthStar’s proposed Beloit, Wis. facility.
MADISON, WI – September 26, 2012 – NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin. The facility will be built to suit for lease. Once complete, the facility
MADISON, WI – September 5, 2012 – NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Stateline Angel Investors of Rockford, Illinois, was the lead investor, joined by existing NorthStar investor Hendricks
(MADISON, Wis. – Nov. 1, 2011) – NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative for the company’s medical isotope production program. The cooperative agreement will be funded under a 50-50 cost share arrangement between NMR and
WILMINGTON, N.C.—September 12, 2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill. Mo-99 decays into technetium-99m, an isotope
MADISON, Wis. –Sept. 8 — NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward’s 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s bioscience industry. The Emerging Company Showcase
(MADISON, WI. – April 7, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Molybdenum-99 is used to
(MADISON, WI. – March 1, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. This agreement allows NorthStar to ramp up over time to 3,000 6-day curies per week. Production operations are expected to begin
Questions?
Do you have questions about NorthStar, our products, supply solutions, careers or anything else?
